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 39 
Summary 40 
Background: 41 
Liraglutide 3·0 mg reduced body weight and improved glucose metabolism after the 56-week period 42 
of this trial, one of four trials comprising the SCALE programme. The primary objective of the 3-43 
year SCALE Obesity and Prediabetes trial was to evaluate the proportion of individuals with 44 
prediabetes who were diagnosed with type 2 diabetes.  45 
Methods: 46 
In this 3-year double-blind trial, 2254 adults with prediabetes and a body-mass index of at least 30 47 
kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based 48 
system, to once-daily subcutaneous liraglutide 3·0 mg or placebo, as an adjunct to a reduced-calorie 49 
diet and increased physical activity. Time to diabetes onset after 160 weeks was the primary 50 
endpoint, evaluated in randomised treated individuals with at least one post-baseline assessment. The 51 
trial was conducted at 191 sites in 27 countries and is registered with ClinicalTrials.gov, number 52 
NCT01272219. 53 
Findings:  54 
The study ran between June 1, 2011, and March 2, 2015; 791 of 1505 (52·6%) participants 55 
randomised to liraglutide and 337 of 749 (45·0%) randomised to placebo completed 3 years. By 56 
week 160, 26 of 1472 individuals in the liraglutide group vs 46 of 738 in the placebo group were 57 
diagnosed with diabetes while on treatment. For the 26 individuals in the liraglutide group, the mean 58 
time from randomisation to diagnosis was approximately 99±47 weeks vs 87±47 weeks for the 46 59 
individuals in the placebo group. Taking the different diagnosis frequencies between the treatment 60 
groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals 61 
was 2·7 times longer with liraglutide than with placebo (95% CI, 1·9 to 3·9, p<0·0001), 62 
corresponding to a hazard ratio of 0·21 (95% CI, 0·13 to 0·34). Liraglutide induced greater weight 63 
 4 
loss than placebo at week 160 (-6·1±7·3% vs -1·9±6·3%, estimated treatment difference -4·3% [95% 64 
CI, -4·9 to -3·7], p<0·0001). Serious adverse events were reported by 15·1% of randomised treated 65 
individuals in the liraglutide group vs 12·9% in the placebo group. 66 
Interpretation:  67 
This trial provides results for up to 3 years of treatment, with the limitation that withdrawn 68 
individuals were not followed up after discontinuation. Liraglutide 3·0 mg may provide health 69 
benefits in terms of reduced diabetes risk in individuals with obesity and prediabetes. 70 
Funding: 71 
Novo Nordisk, Denmark.  72 
 5 
Research in context 73 
Evidence before this study 74 
We searched PubMed from Jan 1, 1990, to April 30, 2016, using the terms “obesity” and 75 
“liraglutide” and “randomised clinical trial”. We found 45 articles assessing liraglutide treatment, 76 
including one phase 1 study, seven randomised controlled studies and seven review articles that 77 
evaluated liraglutide at a dose of 3·0 mg for weight management. Of those, one randomised 78 
controlled study was performed in individuals with and without prediabetes over a 56-week 79 
treatment period. According to study design, individuals who had prediabetes at screening continued 80 
on treatment for a further two years, and are the subject of the current report.  81 
Added value of this study 82 
Few trials of anti-obesity medications have been performed over 3 years. This study provides 83 
clinically important long-term data on the efficacy and safety of liraglutide 3·0 mg in individuals 84 
with prediabetes treated for 3 years followed by a 12-week off-treatment follow-up period. 85 
Treatment with liraglutide 3·0 mg over 3 years was associated with a reduced risk of type 2 diabetes, 86 
weight loss and improvements in glycaemic control in individuals with prediabetes. Liraglutide 3·0 87 
mg was generally well tolerated and no new safety signals were observed as compared to the 88 
previous evaluation after 56 weeks of treatment. 89 
Implications of all the available evidence 90 
Treatment with once-daily subcutaneous liraglutide 3·0 mg for 3 years, combined with a reduced-91 
calorie diet and increased physical activity, may not only provide a sustained clinically relevant 92 
weight loss, but also additional health benefits in terms of reduced risk of type 2 diabetes, as well as 93 
improvements in glycaemic control in a high-risk group of individuals with prediabetes and 94 
overweight/obesity. 95 
 96 
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Introduction 97 
Prediabetes and obesity are risk factors for type 2 diabetes mellitus1–3 and its complications.3 The 98 
prevalence of diabetes is increasing,1–3 and 5–10% of people with prediabetes develop diabetes 99 
yearly.4 Weight loss through lifestyle intervention, with or without pharmacotherapy, can reduce the 100 
risk of developing diabetes.4–9 101 
 102 
Once-daily subcutaneous liraglutide 3·0 mg, as an adjunct to a reduced-calorie diet and increased 103 
physical activity, is approved for weight management in several regions including North America 104 
and Europe. Liraglutide promotes weight loss through reduced appetite and energy intake.10 The 56-105 
week part of the current trial was reported previously and evaluated the efficacy and safety of 106 
liraglutide 3·0 mg for weight loss over 56 weeks.11 Liraglutide 3·0 mg provided substantial weight 107 
loss in individuals with or without prediabetes who had obesity or overweight with comorbidities, 108 
and reduced type 2 diabetes incidence. Individuals who had prediabetes at screening continued on 109 
treatment in the trial for a further two years, and are the subject of the current report. 110 
 111 
This 3-year trial aimed to evaluate the effect of liraglutide 3·0 mg in delaying the onset of type 2 112 
diabetes in individuals with prediabetes, as well as on weight loss and safety over 3 years. 113 
 114 
Methods 115 
Study design 116 
SCALE Obesity and Prediabetes was conducted as part of a large global phase 3a clinical 117 
development programme of 4 randomised, double-blind, placebo-controlled trials with over 5000 118 
participants that was designed to investigate the efficacy and safety of liraglutide 3·0 mg, a 119 
glucagon-like peptide-1 (GLP-1) receptor agonist (RA), for weight management .11-14 We conducted 120 
the study at 191 sites in 27 countries in Europe, North and South America, Asia, Africa and 121 
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Australia. The study design is shown in the appendix p 9. The protocol was approved by local ethics 122 
committees or institutional review boards and is available with the full article text at thelancet.com. 123 
The study was conducted according to the Declaration of Helsinki15 and Good Clinical Practice.16 124 
The 56-week period of the trial evaluated the efficacy and safety of liraglutide 3·0 mg for weight 125 
management in individuals with and without prediabetes.11 The methodology is summarised below. 126 
From week 56, individuals with prediabetes at screening continued on treatment for a further two 127 
years, with a 12-week off-treatment follow-up period. Thus individuals with prediabetes were on 128 
treatment for up to 3 years.  129 
 130 
Participants 131 
We enrolled adults aged ≥18 years with stable body weight and a body-mass index (BMI) of 132 
≥30 kg/m2, or ≥27 kg/m2 with treated or untreated dyslipidaemia and/or hypertension. Each 133 
individual provided written informed consent before participation. Key exclusion criteria were type 1 134 
or 2 diabetes, medications causing significant weight gain or loss, bariatric surgery, history of 135 
pancreatitis, major depressive or other severe psychiatric disorders, and family or personal history of 136 
multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma. Detailed eligibility and 137 
exclusion criteria are provided in the appendix p 31. 138 
 139 
Randomisation and masking 140 
Participants were randomly assigned, in a 2:1 ratio, to receive liraglutide 3·0 mg or placebo. 141 
Randomisation was performed using a sponsor-provided telephone or web-based system. The 142 
sponsor generated the random allocation sequence, and the trial investigators enrolled individuals, 143 
and assigned them to treatment. Participants were stratified at screening by BMI (≥30 vs <30 kg/m2) 144 
and according to whether or not they had prediabetes. Those who had prediabetes and completed 56 145 
weeks of treatment continued for an additional 104 weeks of treatment, allowing for a total of 160 146 
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weeks of treatment. Participants without prediabetes were on treatment for 56 weeks, followed by a 147 
12-week re-randomised period; results for this period of the trial have been reported previously.11 148 
Participants without prediabetes are not included in the current report, thus the stratification factor 149 
was not included in the statistical analysis. Participants and investigators were blinded to treatment 150 
allocation during the entire trial (160 weeks plus the 12-week off-treatment follow-up period), 151 
whereas the sponsor was unblinded to treatment allocation at week 56.  152 
 153 
Procedures and treatments 154 
The current report covers participants with prediabetes who were randomised to treatment for the full 155 
3-year period. The diagnosis of prediabetes was based on fulfilment of at least one of the three 156 
American Diabetes Association (ADA) 2010 criteria: glycated haemoglobin 5·7−6·4% both 157 
inclusive and/or fasting plasma glucose ≥5·6 mmol/L and ≤6·9 mmol/L and/or 2-hour post-challenge 158 
plasma glucose ≥7·8 mmol/L and ≤11·0 mmol/L.17 Diagnosis of diabetes was confirmed by two 159 
consecutive measurements of the same type of criteria: glycated haemoglobin ≥6·5% and/or fasting 160 
plasma glucose ≥7·0 mmol/L and/or 2-hour post-challenge plasma glucose ≥11·1 mmol/L.17 161 
Liraglutide and placebo were provided in prefilled FlexPen devices (Novo Nordisk A/S, Bagsværd, 162 
Denmark), starting at 0·6 mg with weekly 0·6-mg incremental increases to 3·0 mg. All trial 163 
participants received standardised lifestyle intervention counselling from randomisation to end of 164 
follow-up, at approximately monthly intervals (appendix p 3). Participants were advised to achieve at 165 
least 150 minutes of physical activity per week and to reduce their daily energy intake to 500 kcal 166 
below their individualised energy requirement.  167 
 168 
Efficacy and safety endpoints 169 
The primary objective was to evaluate the proportion of individuals with type 2 diabetes at 160 170 
weeks, with time to onset of diabetes as the primary endpoint. This was the fourth coprimary 171 
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endpoint of the trial; the first three coprimary endpoints, mean weight loss and the proportion of 172 
participants losing ≥5% and >10% of their baseline body weight, were met at week 56.11 Secondary 173 
endpoints included changes from baseline to week 160 in glycaemic control parameters, mean and 174 
categorical body weight, BMI, waist circumference, cardiometabolic biomarkers, and health-related 175 
quality of life, assessed using validated questionnaires.18-20 Additional methodology, including 176 
timing of assessments, is described in the appendix p 3. 177 
 178 
Specific adverse events with increased prevalence among people with obesity, or of relevance to the 179 
GLP-1 drug class were assessed (as described in the appendix p 33). Independent medical experts 180 
prospectively adjudicated 9 of 17 event types in a blinded manner. We report adverse events that 181 
occurred during the 160-week trial period, from the first treatment day to 14 days after the last 182 
treatment day, unless otherwise stated. 183 
 184 
Statistical analysis 185 
A sample size of 3600 randomised individuals, 2400 to liraglutide 3·0 mg and 1200 to placebo, was 186 
chosen to provide an assessment of the safety and efficacy of liraglutide 3·0 mg over 3 years. This 187 
provided enough power for the primary endpoint of the 3-year trial, the fourth coprimary endpoint, 188 
which was the long-term efficacy of liraglutide 3·0 mg in delaying onset of diabetes in individuals 189 
with a diagnosis of prediabetes at screening, as reported here. Superiority for liraglutide 3·0 mg vs 190 
placebo was tested in a hierarchical manner with respect to the four coprimary endpoints to control 191 
for multiple testing, whereby the second, third and fourth endpoints were tested only if the previous 192 
endpoint had achieved statistical significance. 193 
 194 
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For the power estimation, a conservative approach was chosen using the binary endpoint type 2 195 
diabetes “yes vs no” assessed in completers during the 160 weeks of treatment and analysed with a 196 
two-sided Chi-square test with a 5% significance level.  197 
 198 
It was assumed that the annual conversion rate to type 2 diabetes of the individuals with prediabetes 199 
would be 7% in the placebo group and 2·1% in the liraglutide 3·0 mg group, i.e., 70% lower. After 200 
160 weeks of treatment, the percentage of individuals with diabetes was therefore estimated to be 1-201 
(1-0·07)3 or 20% among individuals in the placebo group, and 1-(1-0·021)3 or 6% among those in the 202 
liraglutide group. The drop-out rate during the 160 weeks of treatment was assumed to be 65% in 203 
both groups.  204 
 205 
The prespecified efficacy analyses used data from the full-analysis set of all randomised individuals 206 
who received at least one treatment dose and had at least one post-baseline assessment. The safety-207 
analysis set included all randomised individuals who received at least one treatment dose. Missing 208 
values were imputed using last-observation-carried-forward for post-baseline measurements. The 209 
primary endpoint of the 3-year trial was analysed using a Weibull model, using methods for the 210 
analysis of interval-censored time-to-event data. The Weibull model included treatment, sex and 211 
baseline BMI stratum as fixed effects, and baseline fasting glucose value as a covariate. Mean 212 
changes in continuous endpoints were analysed using an analysis of covariance. Categorical changes 213 
for dichotomous endpoints were analysed with logistic regression. Sensitivity analyses were 214 
performed to assess the robustness of the primary analysis, and the analyses for mean and categorical 215 
weight loss (appendix p 36).  216 
 217 
The handling of missing data has progressed since the prespecified analyses were defined,21 therefore 218 
additional post-hoc analyses were specified to further address the issue. A post-hoc Cox regression 219 
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analysis was done at week 172 in which diabetes status was imputed for all withdrawn individuals. It 220 
was firstly assumed that 1% of withdrawn individuals in the liraglutide 3·0 mg group had 221 
undiagnosed diabetes at withdrawal (based on the five additional cases observed in the 12-week off-222 
treatment follow-up period), whereas it was assumed that none of those withdrawn in the placebo 223 
group did so. It was secondly assumed that the risk of developing diabetes after withdrawal in 224 
individuals who did not have diabetes at withdrawal (diagnosed or undiagnosed) was the same in 225 
both treatment groups.  226 
 227 
Five prespecified subgroup analyses were performed to investigate whether baseline BMI (four 228 
categories) had any effect on weight or glycated haemoglobin level (see the appendix p 4). All 229 
statistical analyses in the trial were performed with SAS software, version 9·3 (SAS Institute). 230 
Additional statistical analysis details are included in the appendix. The trial is registered with 231 
ClinicalTrials.gov, number NCT01272219. 232 
 233 
Role of the funding source 234 
The sponsor, Novo Nordisk, participated in discussions regarding study design and protocol 235 
development, and provided logistical support during the trial. The sponsor collected the data, and 236 
planned and performed the statistical analyses, which were assessed by both authors and sponsor. 237 
The authors interpreted the data in collaboration with the sponsor, and wrote the report together with 238 
medical writing services provided by the sponsor. The corresponding author had full access to all 239 
data and had final responsibility for the decision to submit for publication. 240 
 241 
Results 242 
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Trial population 243 
The study was conducted between June 1, 2011, and March 2, 2015. A total of 2254 individuals with 244 
prediabetes, based on ADA 2010 criteria,17 were randomised to 3 years of lifestyle intervention plus 245 
treatment with liraglutide 3·0 mg (n=1505) or placebo (n=749); see the trial profile in figure 1. In the 246 
liraglutide group, 791 of 1505 participants (52·6%) completed 160 weeks of treatment, as did 337 of 247 
749 participants (45·0%) in the placebo group. A greater proportion of participants in the liraglutide 248 
group than the placebo group withdrew owing to adverse events (13·3% [199 of 1501 participants] vs 249 
6·2% [46 of 747]). A smaller proportion of participants in the liraglutide group than in the placebo 250 
group withdrew owing to ineffective therapy (1·9% [29 of 1505 participants] vs 4·8% [36 of 749]) or 251 
withdrew their consent to remain in the trial (21·5% [324 of 1505] vs 31·1% [233 of 749]). 252 
Individuals who withdrew were slightly younger than the average trial population; otherwise, no 253 
noteworthy differences in baseline characteristics or medical history were observed (appendix p 35). 254 
The full-analysis set comprised 1472 participants in the liraglutide group and 738 participants in the 255 
placebo group. 256 
 257 
Baseline characteristics of each group were similar (table 1; additional characteristics are shown in 258 
the appendix p 35).  259 
 260 
Type 2 diabetes diagnosis 261 
By week 160, 26 of 1472 individuals in the liraglutide group vs 46 of 738 in the placebo group were 262 
diagnosed with diabetes while on treatment. Figure 2A shows the Kaplan-Meier plot of cumulative 263 
probability of a diagnosis of diabetes taking censoring into account; 3% of individuals in the 264 
liraglutide group vs 11% in the placebo group were diagnosed with diabetes by week 160.  265 
 266 
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For the 26 individuals in the liraglutide group, the mean time from randomisation to diagnosis was 267 
approximately 99±47 weeks vs 87±47 weeks for the 46 individuals in the placebo group, in a post-268 
hoc analysis. Taking the different diagnosis frequencies between the treatment groups into account, 269 
the time to onset of diabetes over 160 weeks among all randomised individuals, while on treatment, 270 
was 2·7 times longer with liraglutide than with placebo (95% confidence interval [CI], 1·9 to 3·9, 271 
p<0·0001) (appendix p 10). Hence the time to any specific percentile (for instance 1% or 10%) of the 272 
randomised population that will be diagnosed with diabetes is prolonged by a factor of 2·7 for 273 
individuals treated with liraglutide instead of placebo, corresponding to a hazard ratio of 0·21 (95% 274 
CI, 0·13 to 0·34) and a risk reduction of approximately 80% for liraglutide vs placebo.  275 
 276 
Results were consistent across sensitivity analyses, and the treatment difference remained 277 
statistically significant after the 12-week off-treatment follow-up period, with five vs one additional 278 
individuals being diagnosed with diabetes with liraglutide vs placebo, respectively (appendix p 11). 279 
An additional post-hoc analysis was done at week 172 that addressed the lack of follow-up 280 
information for withdrawn participants, and assumed that 1% of those withdrawn in the liraglutide 281 
group had undiagnosed diabetes at withdrawal, whereas none of those in the placebo group did. The 282 
analysis provided a hazard ratio of 0·34, 95% CI, 0·22 to 0·53, p<0·0001, corresponding to a risk 283 
reduction of approximately 66%. 284 
 285 
Regression to normoglycaemia 286 
While on treatment, more individuals in the liraglutide 3·0 mg group (970 of 1472; 66%) than the 287 
placebo group (268 of 738; 36%) had regressed from prediabetes to normoglycaemia by week 160 288 
(odds ratio 3·6 [95% CI, 3·0 to 4·4], p<0·0001; figure 2B), corresponding to a number-needed-to-289 
treat of 3. After a 12-week treatment cessation, some individuals in the liraglutide group reverted to 290 
prediabetes but 740 of 1472 randomised and exposed individuals (50%) still had normoglycaemia at 291 
 14 
week 172 compared to 263 of 738 (36%) of those in the placebo group (odds ratio 1·9 [95% CI, 1·6 292 
to 2·3], p<0·0001). 293 
 294 
Glycaemic control 295 
While on treatment, measures of insulin resistance and beta-cell function improved in the liraglutide 296 
group vs the placebo group at week 160 (appendix p 37), and glycated haemoglobin, fasting glucose, 297 
and fasting insulin levels were lower with liraglutide than with placebo (table 2). Effects on fasting 298 
insulin and HOMA-IR were sustained after treatment cessation from week 160–172; effects on 299 
fasting glucose and glycated haemoglobin were not (figure 2C).  300 
 301 
Body weight 302 
Liraglutide induced greater weight loss than placebo at week 160 while on treatment (-6·1±7·3% vs 303 
-1·9±6·3%, estimated treatment difference -4·3% [95% CI, -4·9 to -3·7], p<0·0001). Weight loss 304 
with liraglutide treatment was sustained over 3 years (figure 3A). Greater mean and categorical 305 
weight loss were achieved in the liraglutide group vs the placebo group (table 2 and figure 3). After 306 
treatment cessation at week 160, some weight was regained in the liraglutide group, although the 307 
treatment difference was still significant at week 172 (-3·2% [95% CI, -4·3 to -2·2], p<0·0001; 308 
appendix p 38). 309 
 310 
Several sensitivity analyses confirmed the superiority of liraglutide over placebo on mean weight 311 
loss, as presented in the appendix p 37. Treatment effects for weight-related endpoints and glycated 312 
haemoglobin were consistent across BMI subgroups (appendix p 18). 313 
 314 
Of note, more than 90% of individuals in each treatment group who were diagnosed with diabetes 315 
lost less body weight than the treatment group mean at the time of diagnosis (appendix p 20). 316 
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 317 
Cardiometabolic variables 318 
Systolic blood pressure was significantly decreased with liraglutide vs placebo at week 160 while on 319 
treatment; diastolic blood pressure was not (table 2). Effects on fasting lipids and cardiovascular 320 
biomarkers were generally modest (appendix p 39), but levels of high-sensitivity C-reactive protein 321 
were substantially lower with liraglutide vs placebo (-36·9% vs -11·0%; estimated treatment 322 
difference -29% [95% CI, -34 to -23], p<0·0001). 323 
 324 
Health-related quality of life 325 
Liraglutide 3·0 mg was associated with higher mean scores on the SF-36 physical component 326 
summary score and the Impact of Weight on Quality of Life–Lite total score, indicating improved 327 
health-related quality of life vs placebo (appendix p 39). 328 
 329 
Safety and tolerability 330 
Gastrointestinal disorders, 93% of mild or moderate severity, were the most common side effects in 331 
the liraglutide 3·0 mg group (table 3), and also the most common cause of withdrawal (118 of 1501 332 
individuals [7·9%] in the liraglutide group vs 11 of 747 [1·5%] in the placebo group) (see the 333 
appendix p 23 for adverse events leading to discontinuation of ≥0·2% individuals in either group). 334 
More serious adverse events were reported in the liraglutide group than the placebo group (table 3). 335 
Adverse event incidence generally declined during the trial (appendix p 25). Four individuals died — 336 
two in the liraglutide group (due to cardiac arrest and metastatic cholangiocarcinoma) and two in the 337 
placebo group (pulmonary failure and cancer, primary tumour unknown). 338 
 339 
As previously reported,11 gallbladder-related events were more common with liraglutide than with 340 
placebo (occurring in 74 of 1501 individuals [4·9%], 2·9 events per 100 patient-years of observation 341 
 16 
(PYO) vs 13 of 747 individuals [1·7%], 1·2 events per 100 PYO). More cases of cholelithiasis and 342 
cholecystitis occurred at relatively constant rates over 3 years in the liraglutide group. Weight loss 343 
among individuals with gallbladder-related events in the liraglutide group was generally greater than 344 
the treatment group mean (appendix p 28). 345 
 346 
Pancreatitis and neoplasms were assessed over 172 weeks, as described in the appendix p 5. Overall, 347 
12 pancreatitis cases (eleven graded as mild, one as moderately severe),22 were confirmed by 348 
adjudication, occurring in ten of 1501 individuals in the liraglutide group (0·7%; 0·3 events per 100 349 
PYO), and in two of 747 placebo-group individuals (0·3%; 0·1 events per 100 PYO). Eight events in 350 
the liraglutide group occurred in the first year, (appendix p 26). Five individuals (four in the 351 
liraglutide group) had gallstone-related pancreatitis, with liver enzyme levels at least three times the 352 
upper limit of the normal range; three individuals (two in the liraglutide group) had gallstones on 353 
imaging.23 354 
 355 
The incidence of adjudicated and confirmed neoplasms was similar in both treatment groups (2·2 vs 356 
2·4 events per 100 PYO). As reported previously,11 a numerical imbalance was observed for 357 
malignant and pre-malignant breast neoplasms: ten events in nine women in the liraglutide group, 358 
seven occurring in the first year, and no events in the placebo group (appendix p 27). Most women 359 
with events had above-average weight loss (appendix p 42). There were no cases of medullary 360 
thyroid carcinoma or C-cell hyperplasia. Liraglutide treatment did not increase median serum 361 
calcitonin concentrations. 362 
 363 
Resting pulse increased in the liraglutide group at week 160 by approximately 2 beats per minute 364 
(table 2). Increases of >5, 10 and 20 beats per minute on at least two consecutive visits are shown in 365 
the appendix p 42. Prespecified cardiovascular events (appendix p 33) occurred in 242 of 1501 366 
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individuals in the liraglutide group (16·1%; 12·1 events per 100 PYO) vs 142 of 747 individuals in 367 
the placebo group (19·0%; 15·1 events per 100 PYO). The incidence of adjudication-confirmed 368 
major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal 369 
stroke) was similarly low in both treatment groups (0·19 vs 0·20 events per 100 PYO). 370 
 371 
No between-group differences were observed for psychiatric disorders, or questionnaire-based 372 
depression or suicidal behaviour scores. However, seven individuals treated with liraglutide (vs none 373 
treated with placebo) reported eight suicidal ideation events and one individual in the placebo group 374 
(vs none in the liraglutide group) reported suicidal depression. There was one suicide attempt in each 375 
treatment group (appendix p 6). 376 
 377 
Results from the 12-week observational follow-up period and additional safety information, 378 
including results on hypoglycaemia, anti-liraglutide antibodies and pregnancies, are provided in the 379 
appendix. 380 
 381 
Discussion 382 
In individuals with overweight or obesity and prediabetes, 3 years of continued treatment with once-383 
daily liraglutide 3·0 mg, as an adjunct to diet and exercise, was associated with lower risk of a type 2 384 
diabetes diagnosis and greater sustained weight loss compared with placebo. 385 
 386 
Generally, lifestyle intervention can induce a 40-70% diabetes relative-risk reduction, and enhance 387 
insulin sensitivity and beta-cell function in individuals with prediabetes at high-risk of developing 388 
type 2 diabetes.4 In both the Diabetes Prevention Program (DPP) and Finnish Diabetes Prevention 389 
Study (DPS), lifestyle intervention compared with placebo was associated with a 58% reduction in 390 
the risk of diabetes after 3 years.6,7 Furthermore, the DPP showed that metformin treatment was 391 
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associated with a 31% risk reduction compared with placebo.6 In a  pharmacotherapy trial in 392 
individuals with obesity, four years of treatment with orlistat was associated with a 37% reduced risk 393 
of diabetes , concomitant with a mean 5·8 kg weight loss vs 3·0 kg with placebo.8 Moreover, two 394 
years of treatment with phentermine/topiramate provided a reduction vs placebo in the annualised 395 
incident rate of type 2 diabetes of 71% or 79%, depending on the dose, in individuals with 396 
prediabetes and/or the metabolic syndrome.9 Mean weight loss was 10·9 and 12·1% for the two 397 
phentermine/topiramate doses vs 2·5% with placebo. Finally, pioglitazone reduced the conversion of 398 
impaired glucose tolerance to type 2 diabetes by 72% compared with placebo after a median 2·4 year 399 
follow-up period, though was associated with significant weight gain.24 The present study addresses 400 
both weight-loss mediated and direct glucose-dependent insulinotropic effects of liraglutide 3·0 mg 401 
on the progression to type 2 diabetes. Liraglutide was associated with an approximate 80% risk 402 
reduction relative to placebo (hazard ratio 0·21) in the onset of type 2 diabetes. However, the 403 
primary analysis did not take into account the lack of follow-up information for withdrawn 404 
individuals. Therefore, a post-hoc analysis was done that made assumptions about those withdrawn 405 
individuals, and provided a risk reduction of approximately 66% relative to placebo (hazard ratio 406 
0·34).  407 
 408 
Whether the lack of a response to treatment for some individuals in the current trial was related to 409 
individual participant characteristics, or due to other factors, is unclear. Most individuals who were 410 
diagnosed with diabetes lost less body weight than the treatment group mean at the time of diagnosis. 411 
 412 
Regression from prediabetes to normoglycaemia was observed in 66% of individuals in the 413 
liraglutide group while on treatment over 160 weeks, and was associated with a lower risk of 414 
diabetes.5 Similar results have been observed previously with liraglutide and other GLP-1 RAs.11, 25–415 
27 The combination of weight loss and glycaemic improvements achieved with liraglutide and 416 
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lifestyle intervention likely contributed to the greater regression to normoglycaemia and  longer time 417 
to onset of diabetes observed. Furthermore, findings from the DPP Outcomes Study demonstrate that 418 
regression to normoglycaemia by any means is associated with a 56% lower risk of diabetes.5,28 419 
Collectively these results support the beneficial use of pharmacotherapy to lower the risk of diabetes 420 
with the potential to reduce cardiovascular risk factors in individuals with obesity and prediabetes.4  421 
  422 
Compared to the DPP, which recruited individuals with impaired fasting glucose and impaired 423 
glucose tolerance, we enrolled a lower-risk, less progressed population as we allowed for fulfilment 424 
of any one of three ADA 2010 diagnostic criteria17 at enrolment. This, together with the weight loss 425 
achieved, may partly explain the lower diabetes incidence of 11% observed in our lifestyle placebo 426 
group, compared to the cumulative incidence of 14·4% at 3 years seen in the DPP for the lifestyle 427 
intervention group and 28·9% in the placebo group.6 428 
 429 
The improvements previously observed11 in body weight, glycaemia and cardiometabolic risk factors 430 
were generally sustained over 3 years. Similar improvements in many of these parameters, such as 431 
high-sensitivity C-reactive protein, have been observed with several GLP-1 receptor agonists,29,30 432 
including liraglutide.12-14 After 12 weeks of treatment cessation, effects on glycated haemoglobin and 433 
fasting glucose disappeared with liraglutide, whereas fasting insulin remained low and unchanged, 434 
supporting differential (direct vs indirect) effects of liraglutide on glucose metabolism and diabetes 435 
risk. As the participants lost more weight with liraglutide than placebo, it will be important for future 436 
studies to quantify the relative contributions of weight loss vs the direct effects of liraglutide on 437 
glucose homeostasis with respect to diabetes risk reduction. 438 
 439 
The safety profile over 3 years was in line with that observed over the initial 56-week period.11 The 440 
numerical imbalance in gallbladder-related events, including cholelithiasis and cholecystitis events 441 
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that occurred at relatively constant rates over 3 years in the liraglutide group, is currently under 442 
investigation. Obesity and weight loss are both associated with an increased risk of gallstone 443 
formation.31 Greater weight loss was generally observed among individuals in the liraglutide group 444 
who reported gallbladder-related events compared to the overall liraglutide population mean. The 445 
cause of the greater number of breast neoplasms in the liraglutide group, 70% of which occurred 446 
during the first year, is still unclear, but weight loss may have increased detection. The underlying 447 
mechanism for the increased resting pulse with liraglutide is also unknown; a direct chronotropic 448 
effect of liraglutide on the sino-atrial node has been suggested.32 449 
 450 
The prevalence of obesity and type 2 diabetes and their associated major comorbidities and 451 
healthcare costs highlight the need for effective treatments. Adverse events in the current trial were 452 
mostly predictable based on the known effects of GLP-1 RAs, including more gastrointestinal 453 
disorders with liraglutide than with placebo, notably nausea, diarrhoea, constipation and vomiting. 454 
Furthermore, the increased pulse associated with liraglutide, as observed with other GLP-1 RAs, did 455 
not lead to an increased cardiovascular risk in a large cardiovascular-outcomes trial with liraglutide 456 
doses up to 1·8 mg.33 In general, liraglutide has a well-documented safety profile based on clinical 457 
trials in over 5000 individuals with obesity and a large clinical development programme in 458 
individuals with diabetes, 33 including extensive post-marketing data. While the frequencies of 459 
gallbladder-related events and pancreatitis were greater in the liraglutide group than in the placebo 460 
group, the incidence of both was relatively low and will be monitored regularly in the post-marketing 461 
setting by routine pharmacovigilance. Overall, the long-term efficacy and safety results for the 462 
current trial support that the benefits of treatment with liraglutide 3·0 mg outweigh the risks in this 463 
already at-risk population of individuals with obesity or overweight with comorbidities. Data 464 
provided here will enable clinicians to attenuate the risks of individuals while optimising the 465 
benefits. 466 
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 467 
Although the 3-year retention rate of 53% in the liraglutide group and 45% in the placebo group can 468 
be considered successful and comparable to another long-term obesity trial,8 the missing data due to 469 
participant withdrawal is a limitation when interpreting the primary endpoint and reported adverse 470 
events. However, a post-hoc analysis accounting for the lack of follow-up information demonstrated 471 
an approximately 66% lower risk of diabetes with liraglutide compared to placebo, the magnitude of 472 
which compares favourably with the 58% lower risk observed in the DPP6 and DPP Outcomes 473 
Study,28 with higher retention and longer follow-up.  474 
 475 
In conclusion, 3 years of treatment with once-daily subcutaneous liraglutide 3·0 mg, as an adjunct to 476 
a reduced-calorie diet and increased physical activity, reduced the risk of type 2 diabetes in 477 
individuals with overweight or obesity and prediabetes, and promoted greater weight loss and 478 
improvements in glycaemic control and cardiometabolic risk factors compared with placebo. 479 
Liraglutide 3·0 mg, as a GLP-1 RA, provides a different treatment option for individuals with obesity 480 
or overweight, with or without type 2 diabetes, having direct glucose-dependent effects on insulin 481 
secretion and weight-loss mediated effects on improved insulin resistance. Liraglutide 3·0 mg was 482 
generally well tolerated. However, post-market surveillance will be exercised to ensure detection of 483 
potential side effects with a very low incidence. 484 
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Table 1. Baseline characteristics of all randomised individuals.*  612 
Characteristic Liraglutide 3·0 mg 
(N=1505) 
Placebo 
(N=749) 
Sex – n (%)   
   Female 1141 (75·8) 573 (76·5) 
   Male 364 (24·2) 176 (23·5) 
Age – years 47·5±11·7 47·3±11·8 
Race – n (%)†   
   White 1256 (83·5) 628 (83·8) 
   Black or African-American 146 (9·7) 71 (9·5) 
   Asian 75 (5·0) 39 (5·2) 
   American Indian or Alaska Native 5 (0·3) 2 (0·3) 
   Native Hawaiian or other Pacific Islander 1 (<0·1) 1 (0·1) 
   Other 22 (1·5) 8 (1·1) 
Hispanic or Latino ethnic group – n (%)† 143 (9·5) 70 (9·3) 
Weight – kg 107·5±21·6 107·9±21·8 
Body-mass index – kg/m2 38·8±6·4 39·0±6·3 
Body-mass index categories – n (%)   
   27-29·9 – overweight 39 (2·6) 23 (3·1) 
   30-34·9 – obesity class I 427 (28·4) 197 (26·3) 
   35-39·9 – obesity class II 492 (32·7) 245 (32·7) 
   ≥40 – obesity class III 547 (36·3) 284 (37·9) 
Waist circumference (all participants) (cm) 116·5±14·4 116·7±13·9 
   Females (n=1141 vs 573) 113·9±13·0 113·8±12·7 
   Males (n=364 vs 176) 124·9±15·0 126·1±13·7) 
Glycated haemoglobin – % 5·8±0·3 5·7±0·3 
Fasting glucose – mmol/L 5·5±0·6 5·5±0·5 
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2-hour plasma glucose during OGTT – mmol/L 7·4±1·8 7·4±1·7 
Fasting insulin – pmol/L 127·6±76·5 125·1±79·1 
Blood pressure – mm Hg   
   Systolic 124·7±12·9 125·0±12·8 
   Diastolic 79·4±8·4 79·8±8·3 
Cholesterol – mmol/L   
   Total 5·0±19·0 5·1±19·0 
   LDL-cholesterol 2·9±27·9 3·0±28·0 
   HDL-cholesterol (all participants) 1·3±26·1 1·3±26·4 
      Females (n=1139 vs 572) 1·4±25·3 1·4±25·1 
      Males (n=363 vs 176) 1·1±22·1 1·1±25·1 
   VLDL-cholesterol 0·7±46·8 0·7±51·3 
   Non-HDL cholesterol 3·6±24·9 3·7±25·0 
Free fatty acids – mmol/L 0·47±39·6 0·48±38·4 
Triglycerides – mmol/L 1·5±54·1 1·5±66·6 
Dyslipidaemia – n (%)‡ 499 (33·2) 249 (33·2) 
Hypertension – n (%)‡ 635 (42·2) 312 (41·7) 
Dyslipidaemia and hypertension – n (%)‡ 317 (21·1) 156 (20·8) 
*Data are observed means ± SD or number (%). For fasting insulin and lipids, data are geometric means and 613 
coefficients of variation. HDL=high-density lipoprotein. LDL=low-density lipoprotein. OGTT=oral glucose-614 
tolerance test. SD=standard deviation. VLDL=very low density lipoprotein. 615 
†Race and ethnic group were self-reported. Participants from France (44 in all) did not report race or ethnic 616 
group. 617 
‡The diagnoses of dyslipidaemia and hypertension were based on reported medical history. 618 
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Table 2: Changes in body weight and cardiometabolic risk factors between baseline and week 619 
160.*  620 
 
 
Endpoint 
Liraglutide 
3·0 mg 
(N=1472) 
Placebo 
(N=738) 
Estimated treatment 
difference, liraglutide 
vs placebo (95% CI)† 
 
 
p value 
Change in body weight     
  % of body weight -6·1±7·3 -1·9±6·3 -4·3 (-4·9 to -3·7) <0·0001 
  Kilograms of body weight -6·5±8·1 -2·0±7·3 -4·6 (-5·3 to -3·9) <0·0001 
  Loss of ≥5% body weight (%)‡ 49·6 23·7 3·2 (2·6 to 3·9) <0·0001 
  Loss of >10% body weight (%)‡ 24·8 9·9 3·1 (2·3 to 4·1) <0·0001 
  Loss of >15% body weight (%)‡ 11·0 3·1 4·0 (2·6 to 6·3) <0·0001 
Body weight-related endpoints    
  Body-mass index (kg/m2) -2·4±2·9 -0·7±2·6 -1·7 (-1·9 to -1·4) <0·0001 
  Waist circumference (all) (cm) -6·9±8·3 -3·4±7·5 -3·5 (-4·2 to -2·8) <0·0001 
    Females (n=1110 vs 565) -7·2±8·3 -3·1±7·3 -4·0 (-4·8 to -3·2) <0·0001 
    Males (n=362 vs 173) -5·9±8·1 -4·3±8·0 -1·9 (-3·4 to -0·5) 0·0080 
Glycaemic control parameters   
  Glycated haemoglobin (% points) -0·35±0·32 -0·14±0·34 -0·21 (-0·24 to -0·18) <0·0001 
  Fasting glucose (mmol/L) -0·37±0·68 0·05±0·62 -0·41 (-0·46 to -0·36) <0·0001 
  Fasting insulin (%) -8·3 1·7 -10·1 (-14·3 to -5·6) <0·0001 
  Fasting C-peptide (%) -4·1 -3·2 -1·3 (-4·4 to 2·0) 0·44 
  PG AUC during OGTT (h*mmol/L) -2·5±6·3 -0·16±7·2 -2·4 (-3·0 to -1·8) <0·0001 
  Insulin AUC during OGTT (%) -0·3 -11·4 11·0 (4·8 to 17·7) 0.0004 
  C-peptide AUC during OGTT (%) -1·7 -10·2 8·8 (4·5 to 13·4) <0·0001 
  2-hour PG during OGTT (mmol/L) -1·6±2·1 -0·2±2·2 -1·4 (-1·6 to -1·3) <0·0001 
Vital signs     
  Systolic blood pressure (mm Hg) -3·2±13·0 -0·5±13·7 -2·8 (-3·8 to -1·8) <0·0001 
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  Diastolic blood pressure (mm Hg) -2·3±9·0 -1·9±9·3 -0·6 (-1·3 to 0·1) 0·09 
  Pulse (beats per minute) 2·1±10·0 -0·02±9·8 2·0 (1·2 to 2·7) <0·0001 
*Data are observed means ± SD, unless otherwise stated, using available data from the full-analysis set, with 621 
last-observation-carried-forward (LOCF) imputation. For insulin and C-peptide, data were log-transformed for 622 
analysis and presented as the relative changes from baseline and relative treatment differences. Post-hoc 623 
analysis was performed for weight loss greater than 15%. Changes from baseline to week 172, after a 12-week 624 
observational follow-up period, are presented in the appendix p 38. 625 
AUC=area under the curve. OGTT=oral glucose-tolerance test. PG=plasma glucose. 626 
†Estimated treatment differences for all endpoints, except pulse, are from an analysis of covariance with 627 
available data from the full-analysis set, with LOCF imputation. The full-analysis set comprised individuals 628 
who underwent randomisation, were exposed to at least one treatment dose, and had at least one assessment 629 
after randomisation (44 individuals were excluded from the full-analysis set: 38 due to lack of an assessment 630 
and 6 due to no exposure). Data on pulse are based on the safety-analysis set, which included all individuals 631 
who underwent randomisation and were exposed to at least one treatment dose.  632 
‡Loss of at least 5%, more than 10%, and more than 15% of body weight were analysed by logistic regression 633 
with data from the full-analysis set (n=1467 in the liraglutide group and n=734 in the placebo group), with 634 
LOCF imputation, and are presented as the proportions of participants (%) and odds ratios.  635 
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Table 3: Adverse events and serious adverse events.*  
Event Liraglutide 3·0 mg (N=1501)  Placebo (N=747) 
  
Participants 
n (%) 
 
 
Events (n) 
Event rate per 
100 years of 
observation 
  
Participants 
n (%) 
 
 
Events (n) 
Event rate per 
100 years of 
observation 
Total number of adverse events 1421 (94·7) 15759 489·6  668 (89·4) 6350 431·9 
Adverse events in ≥5% of individuals 1322 (88·1) 8240 256·0  579 (77·5) 2837 193·0 
Gastrointestinal disorders        
Nausea 614 (40·9) 961 29·9  125 (16·7) 166 11·3 
Diarrhoea 379 (25·2) 610 19·0  107 (14·3) 145 9·9 
Constipation 331 (22·1) 419 13·0  85 (11·4) 100 6·8 
Vomiting 295 (19·7) 472 14·7  40 (5·4) 53 3·6 
Dyspepsia 154 (10·3) 192 6·0  35 (4·7) 40 2·7 
Abdominal pain 114 (7·6) 152 4·7  38 (5·1) 50 3·4 
Abdominal pain upper 112 (7·5) 139 4·3  39 (5·2) 47 3·2 
Gastroesophageal reflex disease 98 (6·5) 110 3·4  18 (2·4) 20 1·4 
Eructation 85 (5·7) 95 3·0  4 (0·5) 4 0·3 
Flatulence 81 (5·4) 94 2·9  20 (2·7) 23 1·6 
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General disorders and administration site conditions     
Fatigue 152 (10·1) 188 5·8  57 (7·6) 66 4·5 
Injection site haematoma 91 (6·1) 102 3·2  60 (8·0) 68 4·6 
Oedema peripheral 53 (3·5) 60 1·9  47 (6·3) 58 3·9 
Infections and infestations        
Nasopharyngitis 396 (26·4) 755 23·5  209 (28·0) 405 27·5 
Upper respiratory tract infection 235 (15·7) 388 12·1  119 (15·9) 212 14·4 
Influenza 181 (12·1) 252 7·8  79 (10·6) 122 8·3 
Gastroenteritis 142 (9·3) 173 5·4  46 (6·2) 53 3·6 
Sinusitis 128 (8·5) 173 5·4  65 (8·7) 111 7·6 
Urinary tract infection 121 (8·1) 176 5·5  43 (5·8) 62 4·2 
Bronchitis 114 (7·6) 139 4·3  62 (8·3) 82 5·6 
Investigations        
Lipase increased 146 (9·7) 208 6·5  23 (3·1) 25 1·7 
Metabolism and nutrition disorders        
Decreased appetite 164 (10·9) 176 5·5  26 (3·5) 27 1·8 
Musculoskeletal and connective tissue disorders       
Back pain 200 (13·3) 287 8·9  120 (16·1) 162 11·0 
Arthralgia 184 (12·3) 229 7·1  97 (13·0) 135 9·2 
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Pain in extremity 108 (7·2) 127 3·9  54 (7·2) 64 4·4 
Nervous system disorders        
Headache 270 (18·0) 427 13·3  122 (16·3) 219 14·9 
Dizziness 146 (9·7) 195 6·1  54 (7·2) 72 4·9 
Respiratory, thoracic and mediastinal disorders       
Cough 111 (7·4) 132 4·1  59 (7·9) 85 5·8 
Oropharyngeal pain 74 (4·9) 81 2·5  44 (5·9) 52 3·5 
Vascular disorders        
Hypertension 75 (5·0) 87 2·7  47 (6·3) 57 3·9 
Total number of serious adverse events 227 (15·1) 350 10·9  96 (12·9) 143 9·7 
Serious adverse events in ≥0·4% of individuals       
Cholelithiasis 20 (1·3) 21 0·7  6 (0·8) 6 0·4 
Cholecystitis acute 9 (0·6) 9 0·3  1 (0·1) 1 <0·1 
Cholecystitis 6 (0·4) 6 0·2  0 0 0 
Osteoarthritis 12 (0·8) 14 0·4  5 (0·7) 6 0·4 
Intervertebral disc protrusion 6 (0·4) 6 0·2  1 (0·1) 1 <0·1 
Back pain 4 (0·3) 4 0·1  3 (0·4) 3 0·2 
Fall 0 0 0  4 (0·5) 4 0·3 
Cellulitis 3 (0·2) 3 0·1  3 (0·4) 3 0·2 
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Obesity 1 (<0·1) 1 <0·1  3 (0·4) 3 0·2 
*Adverse events (grouped by their system organ class) and serious adverse events that occurred up to and including week 162 among individuals in the 
safety-analysis set are included and are presented by their preferred terms from the Medical Dictionary for Regulatory Activities. Events are included if they 
had an onset date on or after the first day that study drug was administered and no later than 14 days after the last day the study drug was administered. 
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Figure legends 
Figure 1: Trial flow diagram  
The 3-year trial population consisted of all individuals with prediabetes, except for those that were 
incorrectly stratified: 37 entered the re-randomised period of the 56-week part of the trial, reported 
previously,15 and are not included below, and 6 with normoglycaemia entered the 3-year part of the 
trial and are included below.  
Figure 2: Liraglutide 3·0 mg and glycaemic status. 
Panel A shows Kaplan-Meier estimates of the proportion of participants who received a diagnosis of 
type 2 diabetes during the course of the trial. Glycaemic status was defined according to American 
Diabetes Association 2010 criteria.21 All individuals for whom diabetes was diagnosed had 
prediabetes at screening, except for one in the placebo group, who had normoglycaemia. The 
numbers along the graph lines show the cumulative number of individuals who received a diagnosis 
of diabetes over the course of 172 weeks. The time until 1% were diagnosed with diabetes was 90 
weeks with liraglutide 3·0 mg and 24 weeks with placebo (post-hoc analysis). Participants were off 
treatment during the 12-week observational follow-up period, but still on diet and exercise. The 
numbers of participants at risk (i.e., remaining in the trial) are shown below the week numbers on the 
x axis. Panel B shows the proportion of participants with prediabetes at screening who regressed to 
having normoglycaemia over the course of 172 weeks. Panel C shows changes in fasting plasma 
glucose (left) and fasting serum insulin (right) over the course of 172 weeks. Relative changes in 
fasting glucose (%) are shown in the appendix p 15. Changes in fasting glucose translated into a 
similar corresponding pattern for glycated haemoglobin changes. Changes in HOMA-IR followed a 
similar pattern as fasting insulin changes. Data shown are the observed means with standard error 
bars (fasting glucose) or with 95% confidence intervals (fasting insulin), and the separate symbols 
represent the 160-week changes using last-observation-carried-forward (LOCF) imputation. 
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Figure 3: Liraglutide 3·0 mg and body weight. 
Panel A shows the mean relative change in body weight for individuals in the full-analysis set who 
completed each scheduled visit. Data shown are the observed means with standard error bars, and the 
separate symbols in the boxes represent the 160-week weight change using last-observation-carried-
forward (LOCF) imputation. The full-analysis set comprised individuals who underwent 
randomisation, were exposed to at least one treatment dose, and had at least one assessment after 
randomisation (44 participants were excluded from the full-analysis set: 38 due to lack of an 
assessment and 6 due to no exposure). Panel B shows the proportions of participants who lost at least 
5%, more than 10%, and more than 15% of their baseline body weight at week 160. Data shown are 
the observed means for the full-analysis set, with LOCF. Findings from a logistic-regression analysis 
showed an odds ratio of 3·2 (95% CI, 2·6 to 3·9) for at least 5% weight loss and an odds ratio of 3·1 
(95% CI, 2·3 to 4·1) for more than 10% weight loss. The analysis for achieving more than 15% 
weight loss was performed post-hoc (odds ratio 4·0 [95% CI, 2·6 to 6·3]).  
